Aesthetic Connect Public Company LimitedSET: TRP🇹🇭 TH

MD&A · 2025

Overview of Operations

Overview of Operations

The company operates in the field of cosmetic facial surgery services under the name 'Teeraporn Hospital'. The medical team consists of specialized experts with extensive experience and wide recognition in the industry. The company offers various services including facelift surgery, eyelid surgery, rhinoplasty (nose surgery), sub-brow lift (brow lift), neck lift, forehead lift, liposuction, fat grafting, breast augmentation, etc., as well as services related to skincare and anti-aging medicine.

2023 - 2025 The company had revenue from services for the year 707.83 million Baht, 533.65 million Baht and 471.45 million Baht, or decreased by 24.61% and declined by 11.66% respectively and the company had net profit for the year ended 192.56 million Baht, 139.37 million Baht and 87.20 million Baht. Representing for 27.01%, 25.12% and 18.11% of the total revenue.

The company’s performance from 2023 to 2025 has declined. This is expected to be due to the economic recession, as well as the fact that the business operates in a popular service industry with many competing brands. As a result, competition in this sector has intensified significantly, both in terms of marketing and pricing. Consequently, customers now have a wider range of options and greater flexibility when choosing services in this field.

In 2023, the Company has transformed from a limited company to a public company limited. It was approved to change its share par value from Baht 10 per share to Baht 0.50 per share resulting change in numbers of common shares from 13 million shares to 260 million shares.

In addition the Company to increase its authorized share capital from Baht 130 million to Baht 175 million to support the stock initial public offering in Market for Alternative Investment (MAI). And the dividend has been paid to shareholders from the Company's retained earnings as of 31 December 2022 at the rate of Baht 1.027 per share, totaling Baht 267.02 million. The dividend is due to be paid by March 31, 2023, and the Company pays dividends to shareholders using the Company's cash flow.

At the Board of Directors Meeting held on November 9, 2023, it was approved to pay interim dividend from the net profit for 9 months ended September 30, 2023 at 0.10 per share of 350 million shares totaling Baht 35 million on December 8, 2023.

At the Board of Directors’ meeting held on February 22,2024 it was approved to propose at the Annual General Meeting of the shareholders to pay dividend from retained earnings at Baht 0.30 per share of 350 million shares totaling 105 million Baht.

In 2024 At the Board of Directors' meeting held on February 21,2025 passed resolutions Approved to propose at the Annual General Meeting of the shareholders to pay dividend form the net profit for the year at Baht 0.20 per share of 350 million shares totaling Baht 70 million. and approved the buy back shares scheme for the Company’s financial management at the limited amount not more than Baht 120 million for not more than 14 million shares which are accounting for 4% of its total paid-up shares (par value Baht 0.50 per share). The buy back period was set to be from March 3, 2025 to September 2, 2025 in which the Board of Directors shall determine the selling method and period of the treasury shares later.

On August 14, 2025, the Company’s Board of Directors meeting approved the amendment to the share repurchase program for the Company’s financial management. The maximum budget remains not exceeding 120 million baht, while the maximum number of shares to be repurchased was increased from 14 million shares to 21 million shares, with no other changes to the conditions.

In 2025, the Company repurchased ordinary shares under the aforementioned program totaling 20.21 million shares, with a total value of 119.89 million baht, representing 5.77% of the issued and paid-up shares. The Company has appropriated 119.89 million baht from retained earnings as a reserve for treasury shares.

This is in accordance with the letter of the Office of the Securities and Exchange Commission (SEC), No. Kor.Lor.Tor. ChorSor. (Wor) 2/2548, dated February 14, 2005, regarding share repurchases, which stipulates that a public limited company may repurchase its shares only up to the amount of its retained earnings. The company is also required to set aside retained earnings as a reserve equal to the amount paid for the share repurchase until all repurchased shares are resold or until the paid-up capital is reduced by cancelling the remaining treasury shares, as the case may be.

On February 27, 2026, the Company’s Board of Directors resolved to propose to the shareholders’ meeting the payment of dividends from the net profit for the year 2025 at the rate of Baht 0.25 per share for 329.79 million shares, totaling Baht 82.45 million.

Operating Results & Financial Condition

Operating Results & Profitability

Analysis of operating results and financial position Based on information from the Company's financial statements. For the year ended December 31, 2023 – 2024 and for the year ended December 31, 2025, the revenue structure details are as follows:

Revenue from services

For the years 2023–2024 and for the year ended December 31, 2025, the Company generated service revenue of 707.83 million baht, 533.65 million baht, and 471.45 million baht, respectively. This represents an increase (decrease) of (24.61%) and (11.66%), respectively, compared to the corresponding periods.


Revenue from surgery-related services

In 2023-2024 and for the year ended December 31, 2025, the Company's revenue from surgical procedures was 657.79 million baht 487.21 million baht and 424.58 million baht, Percent of revenue services was 92.93 percent 91.30 percent and 90.06 percent, respectively. The main revenue comes from Face-Lock Facelift, Eye-Lock Eyelid Surgery Rhinoplasty Surgery and Other Surgery.

In 2023, the company generated revenue of 657.79 million baht from surgery-related procedures, accounting for 92.93% of total service revenue. This included 436.95 million baht from facelift surgeries, 133.03 million baht from eye surgeries, 38.96 million baht from nose surgeries, and 48.85 million baht from other surgical procedures. The revenue from surgery-related procedures in 2023 decreased by 138.28 million baht, representing a decline of 17.37% compared to 2022.

In 2024, the company generated revenue of 487.21 million baht from surgery-related procedures, accounting for 91.30% of total service revenue. This included 292.98 million baht from facelift surgeries, 106.00 million baht from eye surgeries, 28.52 million baht from nose surgeries, and 59.71 million baht from other surgical procedures. Revenue from surgery-related procedures decreased by 170.58 million baht, representing a decline of 25.93% compared to the same period in 2023.

For the year ended December 31, 2025, the company generated revenue of 424.58 million baht from surgery-related procedures, accounting for 90.06% of total service revenue. This included 222.93 million baht from facelift surgeries, 85.06 million baht from eye surgeries, 27.81 million baht from nose surgeries, and 88.77 million baht from other surgical procedures. Revenue from surgery-related procedures decreased by 62.63 million baht, representing a decline of 12.86% compared to the same period in 2024.

The company’s performance from 2023 to 2025 has declined. This is expected to be due to the economic downturn, as well as the fact that the business operates in a popular service industry with numerous competing brands. As a result, competition in this sector has intensified significantly, both in terms of marketing and pricing. Consequently, customers have a wide range of options and greater flexibility when choosing services in this field.Another factor in 2025 was the slowdown in Cambodian customers due to international conflicts. The decrease in revenue was mainly attributable to the following factors:

  1. Revenue from facelift surgery decreased by 70.04 million baht, representing a decline of (23.91%) compared to the same period in 2024. This was due to a decrease in customers for two high-priced facelift service segments.

  2. Revenue from eye surgery decreased by 20.94 million baht, representing a decline of (19.75%), due to a reduction in customers across all types of eye surgery procedures.

  3. Revenue from nose surgery decreased by 0.71 million baht, representing a decline of (2.50%), due to a decrease in customers across all types of rhinoplasty procedures.

However, revenue from other surgical procedures increased by 29.06 million baht, representing a growth rate of 48.67% compared to the same period in 2024. This growth was driven by an increase in customers for procedures such as fat grafting, liposuction, forehead procedures, double chin reduction, buccal fat removal, and breast surgery.


The revenue from Intravenous Anesthesia Services

Certain surgical procedures may require anesthesia to ensure patient comfort, such as facelift surgery and double eyelid surgery. Additionally, anesthesia may be necessary for other surgical cases, particularly for elderly patients or those with underlying health conditions. The anesthesia service is provided through intravenous (IV) sedation, where an appropriate amount of anesthetic is administered before the procedure. This allows patients to feel relaxed and comfortably drowsy while still being able to breathe on their own. IV sedation is considered safer than general anesthesia as it has fewer side effects.

From 2023-2024 and for the year ended December 31, 2025, the company generated revenue from anesthesia services of 30.53 million baht, 23.53 million baht, and 20.48 million baht, respectively. The proportion of anesthesia service revenue to total service revenue was 4.31%, 4.41%, and 4.34%, respectively.


Revenue from Non-Surgical Services

Non-surgical service revenue includes procedures such as dermal filler injections for wrinkle reduction and facial contouring, Botox injections for wrinkle reduction and facial shaping, and other skin-related treatments such as Ultherapy, Ultraclear, Lab check-ups, Hyperbaric Oxygen Therapy, and skin vitamin therapy. Some customers who use non-surgical services are those who have also undergone surgical procedures, seeking additional treatments to enhance or maintain their results.

From 2023-2024 and for the year ended December 31, 2025, the company generated revenue from non-surgical services (Skin Care) of 19.51 million baht, 22.92 million baht, and 26.39 million baht, respectively. The proportion of non-surgical service revenue to total service revenue was 2.76%, 4.29%, and 5.60%, respectively.

Revenue from non-surgical services in 2025 increased by 3.47 million baht, representing a growth rate of 15.14% compared to the same period in 2024. This increase was driven by higher revenue from skin care and anti-aging medical services, such as lab check-ups and anti-aging treatments.

For the year ended December 31, 2025, the Company reported an increase in non-surgical service revenue of 3.47 million baht, or 15.14% compared to the same period in 2024. This growth was attributable to the Company’s efforts to expand its customer base and its ability to generate higher sales in the skin care and anti-aging segments.


Revenue from sales

In 2025, the Company generated revenue of 0.25 million baht from the sale of three skin care products: C-NAD Reju & Repairing Serum, C-Advanced White Plus Peptide Serum, and C-Hyaluron Multi Moisturizing. These products were introduced to provide an additional revenue stream for the Company.

Other Revenue

From 2023-2024 and for the year ended December 31, 2025, the company generated other revenue of 5.20 million baht, 21.19 million baht, and 9.88 million baht, respectively, accounting for 0.73%, 3.80%, and 2.05% of total revenue. This revenue primarily came from interest income on fixed deposits.


Cost of Services

From 2023-2024 and for the year ended December 31, 2025, the company’s cost of services amounted to 319.45 million baht, 252.44 million baht, and 234.76 million baht, respectively. The cost-to-service revenue ratio was 45.13%, 47.30%, and 49.80%, respectively. The main cost components included doctor fees, commissions, employee-related expenses, and costs of medications and medical supplies.

In 2023, the company's cost of services amounted to 319.45 million baht, accounting for 45.13% of service revenue, representing a decrease of 61.06 million baht compared to the same period in 2022. The main cost components were: Doctor fees: 267.65 million baht (37.81% of service revenue) Cost of medications, medical supplies, and other materials: 16.98 million baht (2.40% of service revenue) Employee-related expenses: 19.27 million baht (2.72% of service revenue) The decrease in cost of services was primarily due to a reduction in doctor fees, which declined in line with the decrease in service revenue.

In 2024, the company's cost of services amounted to 252.44 million baht, accounting for 47.30% of service revenue. This represents a decrease of 67.01 million baht, or 20.98%, compared to 2023. The main cost components were: Doctor fees: 199.27 million baht (37.34% of service revenue) Employee-related expenses: 20.27 million baht (3.80% of service revenue) Cost of medications, medical supplies, and other materials: 15.55 million baht (2.91% of service revenue) The decline in service costs was primarily due to the reduction in doctor fees and costs of medications and medical supplies, which decreased in line with the overall decline in service revenue.

For the year ended December 31, 2025, the Company’s cost of services amounted to 234.76 million baht, representing 49.80% of service revenue. This decreased by 17.68 million baht, or 7.00%, compared to 2024.

The main components of the cost of services included physician fees of 170.82 million baht, staff-related expenses of 23.81 million baht, and costs of medicines, medical supplies, and other materials of 18.62 million baht, representing 36.23%, 5.05%, and 3.95% of service revenue, respectively.

The decrease in cost of services was primarily due to a reduction in physician fees, which declined in line with the decrease in service revenue.

Cost of sales

In 2025, the Company recorded a cost of goods available for sale from three skin care products totaling 0.08 million baht.


Gross Profit and Gross Profit Margin

From 2023-2024 and for the year ended December 31, 2025, the company’s gross profit from services amounted to 388.37 million baht, 281.22 million baht, and 236.86 million baht, respectively. The gross profit margin was 54.87%, 52.70%, and 50.21%, respectively.

In 2023, the company’s gross profit from services amounted to 388.38 million baht, representing a gross profit margin of 54.87%. This reflected a 17.91% decline compared to the same period in 2022, in line with the decrease in service revenue. The decline was attributed to changing consumer behavior. From 2020 to 2022, international travel restrictions due to COVID-19 led many individuals to opt for cosmetic procedures during long holidays instead. However, by 2023, as travel returned to normal, some people prioritized tourism over cosmetic surgery, resulting in fewer customers. Additionally, the company’s cost of services decreased by 61.06 million baht, or 16.05%, compared to 2022, aligning with the revenue decline. However, employee-related expenses increased, which contributed to a slight reduction in the gross profit margin compared to the previous year.

In 2024, the Company reported gross profit from services of 281.22 million baht, representing a gross profit margin of 52.70%, or a decrease of (27.59%) compared to the same period in 2023, in line with the decline in service revenue. In addition, the Company’s cost of services decreased by 67.02 million baht, or (20.98%) compared to the same period in 2023, which was consistent with the decrease in revenue.

For the year ended December 31, 2025, the Company reported gross profit from services of 236.86 million baht, representing a gross profit margin of 50.21%. This reflects a decrease of (15.77%), in line with the decline in service revenue of 62.21 million baht, or a decrease of (11.66%)

Selling and Administrative Expenses

From 2023-2024 and for the year ended December 31, 2025, the company’s selling and administrative expenses amounted to 148.12 million baht, 132.68 million baht, and 137.96 million baht, respectively. These expenses accounted for 20.93%, 24.86%, and 29.26% of service revenue for each year. The changes in selling and administrative expenses can be explained as follows:

Selling Expenses

The company's key selling expenses include: Promotional expenses Employee-related expenses Consulting fees and professional service fees The details of selling expenses for the years 2023–2025 are as follows:

In 2023, the company’s selling expenses amounted to 99.08 million baht, accounting for 13.99% of service revenue. This represented an increase of 9.80 million baht, or 10.98% growth, compared to 2022. The main factors contributing to this increase were: Higher promotional expenses of 26.74 million baht, driven by increased marketing efforts through both online and offline advertising channels. Employee-related expenses increased by 1.43 million baht. Commission expenses decreased by 14.57 million baht, aligning with the decline in service revenue. Other expenses decreased by 3.8 million baht.

In 2024, the Company’s selling expenses amounted to 84.64 million baht, representing 15.86% of service revenue. This decreased by 14.44 million baht, or (14.57%), compared to the same period in 2023.The primary reason for this decrease was lower promotional and marketing expenses, particularly from reduced advertising through both online and offline channels, amounting to a decrease of 12.33 million baht. This was partially offset by an increase in staff-related expenses of 1.76 million baht, a decrease in commission expenses of 6.66 million baht in line with declining revenue, and an increase in other expenses of 2.79 million baht.

For the year ended December 31, 2025, the Company’s selling expenses amounted to 77.29 million baht, representing 16.39% of service revenue. This decreased by 7.35 million baht, or (8.69%), compared to the same period in 2024. The primary reasons for this decrease were a reduction in advertising and promotional expenses of 4.75 million baht and a decrease in commission expenses of 8.17 million baht, both in line with the decline in revenue. This was partially offset by an increase in other expenses of 5.57 million baht. The Company has also made efforts to optimize and control its promotional spending to achieve maximum efficiency.


Administrative Expenses

Key Administrative Expenses The company's key administrative expenses include: Employee-related expenses Bank fees Depreciation expenses Other administrative expenses The details of administrative expenses for the years 2023–2025 are as follows:

In 2023, the company’s administrative expenses amounted to 49.04 million baht, accounting for 6.93% of service revenue. This represented an increase of 7.07 million baht, or 16.85% growth, compared to 2022. The main factors contributing to this increase were: Expansion of the workforce and management team to support the company’s growth. Preparation expenses related to the company's initial public offering (IPO).

In 2024, the company’s administrative expenses amounted to 48.03 million baht, accounting for 9.00% of service revenue. This represented a decrease of 1.01 million baht, or a decline of 2.06%, compared to 2023. The reduction was mainly due to a decrease in bank fees, consulting fees, and professional service fees, which aligned with the overall decline in revenue. This was a result of the company’s efforts to control and reduce administrative expenses.

For the year ended December 31, 2025, the Company’s administrative expenses amounted to 60.67 million baht, representing 12.87% of service revenue. This increased by 12.64 million baht, or 26.31%, compared to the same period in 2024.

The increase was primarily driven by higher staff-related expenses of 6.95 million baht, resulting from the expansion of operations from a clinic to a hospital, which required additional personnel to adequately support customer services. In addition, depreciation and other expenses increased by 5.69 million baht.

Financial costs

From 2023-2024 and for the year ended December 31, 2025, the company’s finance costs amounted to 1.89 million baht, 0.40 million baht, and 0.12 million baht, representing 0.27%, 0.07%, and 0.03% of service revenue, respectively. Finance costs were solely derived from interest expenses on lease agreements.


Net profit and net profit margin

From 2023 to 2025, the company recorded a net profit of 192.56 million baht, 139.37 million baht, and 87.20 million baht, respectively, representing a net profit margin of 27.01%, 25.12%, and 18.11%, respectively.

In 2023, the company's net profit margin decreased from 31.64% in 2022 to 27.01%. This decline was primarily due to a decrease in revenue, which was likely impacted by economic conditions and political uncertainties in the country. Additionally, as tourism returned to normal after the COVID-19 pandemic, some consumers opted for travel over cosmetic surgery. Furthermore, in 2023, the company experienced higher selling expenses due to increased marketing efforts across both online and offline channels, as well as a rise in administrative staff costs. These factors contributed to a lower net profit margin for the year.

In 2024, the company's net profit margin decreased from 27.01% in 2023 to 25.12%. This decline was primarily due to a drop in revenue, which resulted from the economic recession and the highly competitive nature of the service industry, as it continues to grow in popularity.

For the year ended December 31, 2025, the company’s net profit margin decreased compared to the same period in 2024, from 25.12% to 18.11%. The decline in net profit was mainly due to a decrease in revenue, resulting from economic recession conditions, as well as the fact that the business operates in a popular service sector with very high competition.


The analysis of the financial position statement

As of December 31, 2023 – December 31, 2025, the company’s total assets amounted to 1,795.46 million baht, 1,871.79 million baht, and 1,727.44 million baht, respectively. The company’s main assets include cash and cash equivalents, other current financial assets, land, leasehold improvements and equipment, investment properties, and right-of-use assets, with details as follows:

Cash and cash equivalents

As of December 31, 2023 – December 31, 2025, the company had cash and cash equivalents amounting to 255.30 million baht, 408.16 million baht, and 210.16 million baht, which represent 14.22%, 21.81%, and 12.17% of total assets, respectively.

As of December 31, 2023, the company’s cash decreased by 99.13 million baht compared to December 31, 2022, representing a decrease of 27.97%. This was due to the company paying dividends amounting to 267.02 million baht in Q2/2023 and an interim dividend of 0.10 baht per share, totaling 35 million baht, in Q4/2023.

As of December 31, 2024, the company’s cash increased by 152.86 million baht compared to December 31, 2023, representing an increase of 59.88%. This was due to the company using funds from short-term investments in fixed deposits to prepare reserves for the payment of construction debts related to the hospital, resulting in a higher cash and cash equivalents balance.

As of December 31, 2025, the company’s cash decreased by 197.99 million baht compared to December 31, 2024, representing a decline of 48.51%. This decrease was due to the use of funds from short-term investments in fixed deposits to pay construction payables for the hospital, resulting in a reduction in cash and cash equivalents.

The changes in cash and cash equivalents are primarily due to the impact of the increase or decrease in the company’s net cash from operating activities, investing activities, and financing activities.


Net property, Lease building improvement and equipment

As of December 31, 2023, the company’s land, leasehold improvements, and equipment increased by 70.88 million baht compared to 2022, due to vehicles and assets under construction for the new hospital, which is currently being built.

As of December 31, 2024, the company’s land, leasehold improvements, and equipment increased by 340.13 million baht compared to 2023, due to assets under construction for the new hospital, which is currently being built.

As of December 31, 2025, the company’s property, plant, and equipment increased by 212.63 million baht compared to 2024, mainly due to the transfer of completed construction-in-progress into assets ready for use.


Investment properties

As of December 31, 2023 – December 31, 2025, the company had investment properties amounting to 89.58 million baht, 89.14 million baht, and 88.70 million baht, which represented 4.99%, 4.76%, and 5.13% of total assets, respectively. The properties consisted of land with buildings on an area of 0-3-85 rai located on Charoen Krung Road, valued at 90.46 million baht. When the property was acquired, the company’s management intended to demolish the building and construct a new hospital. However, due to increased revenue, the Extraordinary General Meeting of Shareholders No. 3/2021 on December 3, 2021, resolved to sell the land and building because the space was insufficient. The company then purchased a new piece of land that is larger and more suitable for the hospital’s needs.


Net Right-Use Assets

As of December 31, 2023 – December 31, 2025, the company had right-of-use assets (net) amounting to 13.25 million baht, 3.63 million baht, and 4.52 million baht, which represented 0.74%, 0.19%, and 0.26% of total assets, respectively. The right-of-use assets consist of office buildings and vehicles, with lease terms of approximately 5 to 6 years, In 2025, these consisted of medical equipment, vehicles, and office equipment, with lease terms of approximately 4–5 years. recognized in accordance with Thai Financial Reporting Standard No. 16 (TFRS 16).


Liabilities

As of December 31, 2023 – December 31, 2025, the company had total liabilities amounting to 108.61 million baht, 150.54 million baht, and 107.49 million baht, which represented 6.05%, 8.04%, and 6.22% of total liabilities and shareholders' equity, respectively. The company’s main liabilities include trade payables, other payables, lease liabilities, and current liabilities arising from contracts, with details as follows:


Trade payables and other payables

As of December 31, 2023, the company had trade payables and other payables amounting to 49.98 million baht, an increase of 4.38 million baht compared to 2022. The increase was mainly due to accrued advertising expenses.

As of December 31, 2024, the company had trade payables and other payables amounting to 83.34 million baht, an increase of 33.36 million baht compared to 2022. The increase was mainly due to construction payables for the hospital.

As of December 31, 2025, the company had trade and other payables of 37.62 million baht, a decrease of 45.72 million baht compared to 2024. This decrease was mainly due to payments made to settle payables related to hospital construction.

Lease liabilities

Lease liabilities consist of liabilities under lease agreements for office buildings, vehicles, and office equipment, with lease terms of approximately 4 to 6 years, recognized in accordance with Thai Financial Reporting Standard No. 16 (TFRS 16).

In 2025, lease liabilities consisted of medical equipment, vehicles, and office equipment, with lease terms of approximately 4–5 years. These were recognized in accordance with Thai Financial Reporting Standard No. 16 (TFRS 16).

As of December 31, 2023 – December 31, 2025, the company had lease liabilities amounting to 13.66 million baht, 3.86 million baht, and 3.86 million baht, which represented 0.76%, 0.21%, and 0.22% of total liabilities and shareholders' equity, respectively. These lease liabilities were divided into current lease liabilities due within one year, amounting to 9.91 million baht, 3.65 million baht, and 1.06 million baht, and non-current lease liabilities due beyond one year, amounting to 3.75 million baht, 0.21 million baht, and 2.80 million baht, respectively. In 2025, the company’s lease liabilities decreased due to the expiration of the building lease (Teeraporn Clinic). At the same time, new lease liabilities were recognized from the leasing of medical equipment.

Current liabilities arising from contracts

Current liabilities arising from contracts consist of advance service fees and unrecognized service revenue. As of December 31, 2023 – December 31, 2025, the company had current liabilities arising from contracts amounting to 18.43 million baht, 20.76 million baht, and 22.47 million baht, which represented 1.03%, 1.11%, and 1.30% of total liabilities and shareholders' equity, respectively. The increase in current liabilities arising from contracts was due to the rise in advance service fees received.


Shareholders' equity

As of December 31, 2023 – December 31, 2025, the company’s shareholders' equity amounted to 1,686.85 million baht, 1,721.25 million baht, and 1,619.95 million baht, respectively, representing 93.95%, 91.96%, and 93.78% of total liabilities and shareholders' equity in each period. Shareholders' equity consists of the issued and fully paid-up share capital, share premium, and retained earnings, including legal reserve and unappropriated retained earnings.

In 2023, the company’s shareholders' equity amounted to 1,686.85 million baht, an increase of 1,117.53 million baht, or a 196.29% increase from 2022, due to the company offering 90 million shares to the public for the first time through an Initial Public Offering (IPO) between October 10-12, 2023. The shares had a par value of 0.50 baht per share and were offered at 14 baht per share, raising a total of 1,260 million baht.

Subsequently, on October 16, 2023, the company received full payment for the shares, and the Market for Alternative Investment (MAI) registered 350 million common shares with a par value of 0.50 baht per share. These shares were officially listed, and trading commenced on October 24, 2023, under the services sector, with the trading symbol "TRP."

As of December 31, 2024, the company’s shareholders' equity amounted to 1,721.25 million baht, an increase of 34.40 million baht, or a 2.04% increase from 2023, due to the growth in retained earnings.

As of December 31, 2025, the company’s shareholders’ equity amounted to 1,619.95 million baht, a decrease of 101.30 million baht, or 5.89%, compared to 2024. This decrease was mainly due to a reduction in retained earnings, resulting from lower revenue and a decline in net profit.

Cash flow analysis

As of December 31, 2023 – December 31, 2025, the company had cash and cash equivalents amounting to 255.30 million baht, 408.16 million baht, and 210.16 million baht, which represented 14.22%, 21.81%, and 12.17% of total assets, respectively.

In 2023, the company had cash and cash equivalents at the beginning of the year amounting to 354.43 million baht and generated cash flow from operating activities of 266.19 million baht. This was driven by a profit before tax of 243.55 million baht, adjusted by non-cash items amounting to 13.61 million baht, changes in operating assets and liabilities of 9.03 million baht, and income tax and interest payments of 59.34 million baht. The changes in operating assets and liabilities were mainly impacted by: 1) an increase in trade and other payables by 2.31 million baht, 2) an increase in trade and other receivables by 1.41 million baht, 3) an increase in other current liabilities by 2.82 million baht, and 4) an increase in other non-current liabilities by 2.45 million baht. The company used 1,101.71 million baht in investing activities, which included investments in 6-month fixed deposits and expenditures for the construction of the new hospital. Additionally, the company used 795.74 million baht in financing activities, which included cash received from an Initial Public Offering (IPO) of 90 million shares with a par value of 0.50 baht per share, offered at 14 baht per share, raising a total of 1,260 million baht. The company also paid dividends to shareholders amounting to 302.01 million baht and repaid long-term loans from a financial institution amounting to 109.54 million baht. As a result of the cash flows from all the activities mentioned above, the company had a net decrease in cash flow of 99.13 million baht for the year, leading to a reduction in cash and cash equivalents at the end of the year to 255.30 million baht.

In 2024, the company had cash and cash equivalents at the beginning of the year amounting to 255.30 million baht and generated cash flow from operating activities of 153.11 million baht. This was driven by a profit before tax of 169.23 million baht, adjusted by non-cash items of 3.10 million baht, changes in operating assets and liabilities of 13.02 million baht, and income tax and interest payments of 33.06 million baht. The changes in operating assets and liabilities were mainly impacted by: 1) a decrease in trade and other payables by 21.33 million baht, 2) an increase in contract liabilities by 2.32 million baht, and 3) an increase in trade and other receivables by 8.88 million baht. Additionally, the company generated cash in investing activities of 148.36 million baht by investing short-term deposits from the funds raised through the IPO to reserve for payment to construction creditors for the hospital construction and also earned interest income from those fixed deposits. In financing activities, the company used cash amounting to 115.54 million baht, which included payments for lease liabilities along with interest payments of 10.57 million baht and dividend payments to shareholders totaling 104.97 million baht. As a result of the cash flows from all the activities mentioned above, the company had a net increase in cash flow of 152.86 million baht for the year, leading to an increase in cash and cash equivalents at the end of the year to 408.16 million baht.

In 2025, the company had beginning cash and cash equivalents of 408.16 million baht. Net cash provided by operating activities amounted to 77.42 million baht, primarily derived from profit before tax of 108.66 million baht, adjusted for non-cash items of 13.24 million baht, changes in operating assets and liabilities of 44.48 million baht, and income tax and interest payments totaling 26.94 million baht.Changes in operating assets and liabilities were mainly impacted by: 1) a decrease in trade and other payables of 49.50 million baht, 2) an increase in contract liabilities of 1.71 million baht, and 3) a decrease in trade and other receivables of 0.43 million baht. The company used 55.75 million baht in investing activities, primarily from short-term investments in fixed deposits funded by the IPO, which were partially used for hospital construction and the purchase of equipment, including medical instruments.

In addition, the company used 192.72 million baht in financing activities, including lease liability repayments with interest totaling 4.07 million baht, dividend payments to shareholders of 68.77 million baht, and share repurchases amounting to 119.89 million baht. As a result of the net cash flows from all the above activities, the company’s net cash decreased by 198.00 million baht in 2025, leading to ending cash and cash equivalents of 210.16 million baht.


Analysis of Key Financial Ratios

Liquidity Ratios

As of December 31, 2023 – December 31, 2025, the company had liquidity ratios of 13.08 times, 7.79, and 9.02, respectively.

In 2023, the company’s liquidity ratio increased from 2022 due to an increase in registered capital by 45 million THB, from the original registered capital of 130 million THB to 175 million THB. Between October 10-12, 2023, the company offered newly issued common shares to the public for the first time (Initial Public Offering) on the Market for Alternative Investment (MAI). On October 16, 2023, the company received full payment for the shares issued.

As of December 31, 2024, the company’s liquidity ratio stood at 7.79 times, a decrease from 2023. This was due to the company’s repayment of construction debt for the Theeraporn Hospital and the current liabilities related to the construction creditors of Theeraporn Hospital. As a result, the ratio decreased compared to 2023, but the liquidity ratio remains at a healthy level.

As of December 31, 2025, the company’s current ratio was 9.02 times, an increase from 2024. This was mainly due to the repayment of construction payables for Theeraporn Hospital, resulting in a decrease in current liabilities related to such payables. Consequently, the company’s liquidity ratio improved compared to 2024 and remained at a strong level.

Additionally, when considering the cash cycle from 2023 to 2025, the company had a cash cycle of (50) days, (91) days, and (87) days, respectively. The following is a breakdown of the average collection period, average sales period, and average payment period:

From 2023 to 2025, the company had an average collection period of approximately 0 to 2 days, as most of the customers pay for services upfront before receiving them. This results in the company having a small amount of trade receivables. The company’s average sales period from 2023 to 2025 was 4 days, 5 days, and 7 days, respectively. Furthermore, the company’s average payment period from 2023 to 2025 was 55 days, 96 days, and 94 days, respectively. As of December 31, 2025, the company’s cash cycle was (87) days. These ratios indicate that the company has good liquidity and is effective in managing its working capital.

Profitability Ratios

The company has a gross profit margin for the years 2023-2025 of 54.87%, 52.70%, and 50.21%, respectively. The decrease in gross profit margin from 2023 to 2024 was due to a reduction in service revenue, caused by the economic situation and an increase in competitors within the beauty service industry. For the year ending December 31, 2025, the company saw a decline in service revenue, and service costs also decreased in the same direction, resulting in a reduction in the gross profit margin compared to 2024.

The company has a net profit margin for the years 2023-2025 of 27.01%, 25.12%, and 18.11%, respectively. The continuous decrease in net profit margin follows the same trend as the gross profit margin. However, the net profit margin for the year ending December 31, 2025, decreased due to a decline in service revenue.


The company has a return on equity (ROE) for the years 2023-2025 of 17.07%, 8.18%, and 5.22%, respectively. For the year ending December 31, 2023, the ROE decreased to 17.07%, down from 2022, due to a reduction in net profit, though shareholders' equity increased with an additional 1,332.84 million baht in capital surplus. This was because the company raised its registered capital by 45 million baht, from 130 million baht to 175 million baht. Between October 10-12, 2023, the company conducted an Initial Public Offering (IPO), offering 90 million new shares at 14 baht per share, with a total value of 1,260 million baht. The company received full payment for these shares on October 16, 2023.

The company’s return on equity (ROE) was 8.18% in 2024 and 5.22% in 2025, representing a decline from 2023 and 2024. This decrease was due to weaker operating performance, which led to a reduction in net profit.

Operational Efficiency Ratios

As of December 31, 2023 – December 31, 2025, the company has a return on assets (ROA) of 18.89%, 9.25%, and 6.04%, respectively.

In 2023, the company’s return on assets decreased from 2022 due to a decline in net profit and an increase in assets from the Initial Public Offering (IPO) of 90 million new shares with a par value of 0.50 baht per share, offered at 14 baht per share, raising a total of 1,260 million baht.

In 2024, the company’s return on assets decreased from 2023 due to a decline in net profit, with assets increasing from assets under installation due to the construction of the Teeraporn Hospital.

For the year ended December 31, 2025, the company’s return on assets (ROA) decreased compared to 2024, due to a decline in net profit and an increase in total assets, primarily from assets related to the construction of Teeraporn Hospital.


Monetary Policy Analysis Ratios

As of December 31, 2023 – 2024, and for the year ending December 31, 2025, the company has a debt-to-equity ratio of 0.06, 0.09, and 0.07, respectively.

In 2023, the debt-to-equity ratio decreased due to an increase in registered capital by 45 million baht, from an initial registered capital of 130 million baht to 175 million baht. Between October 10-12, 2023, the company conducted an Initial Public Offering (IPO), offering 90 million new shares at a par value of 0.50 baht per share, at a price of 14 baht per share, raising a total of 1,260 million baht. The company received full payment for these shares on October 16, 2023. As of December 31, 2023, the company had a capital surplus of 1,332.84 million baht.

For the year ending December 31, 2024, the debt-to-equity ratio increased due to higher debt from creditors for the construction of Teeraporn Hospital. Additionally, shareholders' equity decreased due to a reduction in net profit.

For the year ended December 31, 2025, the company’s debt-to-equity ratio decreased compared to 2024. This was mainly due to a reduction in liabilities from the repayment of payables related to the construction of Theeraporn Hospital. In addition, shareholders’ equity also declined as a result of lower net profit.

As of December 31, 2023 – 2024, and for the year ending December 31, 2025, the company has an interest coverage ratio of 157.53, 466.92, and 1,073.53, respectively. These ratios reflect the company's strong ability to meet interest payments. In 2023, the interest coverage ratio increased because, in October 2023, the company fully repaid the long-term loan to the financial institution, which led to a decrease in interest payments.

For the years ended December 31, 2024 and December 31, 2025, the company’s interest coverage ratio increased, as only interest expenses related to lease liabilities remained.

Debt Securities with Financial Ratio Requirements

Debt Securities with Financial Ratio Requirements Issued?

No

Factors That May Affect Financial Condition

Factors or Incidents That May Materially Affect Financial Condition

Commitment to Transformation from a Clinic to a Hospital

To enhance credibility among clients receiving services from both domestic and international markets, while also improving service efficiency—this includes increasing the number of operating rooms to accommodate more complex cases, expanding space for dermatology and wellness departments, and enlarging customer service areas such as waiting areas and parking facilities. These efforts aim to create a superior experience for all clients.

Commitment to Becoming an Internationally Accredited Hospital with AACI Standards

In addition to transitioning into a hospital, the Company has obtained AACI accreditation, as well as ISO 9001:2015 and ISO 7101:2023 certifications, in order to further strengthen customer confidence.

Development of the Hospital Ecosystem and Adoption of Renewable Energy

The hospital has invested in installing solar cells to help reduce greenhouse gas emissions, particularly carbon dioxide, from conventional electricity generation. This also mitigates risks from future fluctuations in electricity prices (FT), enabling the organization to forecast operating costs more accurately. Additionally, the Company has transitioned to LED lighting to reduce energy consumption. Furthermore, the Company has invested in a Hospital Information System (HIS), which enhances data management efficiency, accuracy, and operational speed, while also reducing paper usage and storage space within the organization.

The impact of the conflict situation between Thailand and Cambodia.

Data from 2025–2026 indicates that border conflicts and checkpoint closures have had a direct impact on Cambodian customers, who are a high-spending segment in the cosmetic surgery market. The unrest has led to a significant decline in the number of Cambodian patients and has negatively affected confidence in cross-border travel.

The impact of global unrest.

Prolonged wars affect flight routes and energy costs, leading to higher airfares. This may pose a barrier for long-haul medical tourism markets, such as Europe and the United States. Additionally, the global economic slowdown may impact consumers’ purchasing power worldwide.

The impact of inflation and rising costs.

Rising costs of medical supplies, imported medical equipment, and electricity may increase the company’s overall expenses.

Contents